Share:
-Facility to supply drug product for planned Phase 3 clinical trials and early access programme
Cambridge Allergy Ltd ( Camallergy or the Company ), a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced that its manufacturing facility outside of Portsmouth, United Kingdom was approved by the MHRA, the Medicines and Healthcare products Regulatory Agency, to manufacture its proprietary peanut allergy treatment under current Good Manufacturing Practices (cGMP) standards. This clearance is a pivotal regulatory milestone that further supports Camallergy s leadership and capabilities in the field of peanut allergy immunotherapy with the only cGMP-certified manufacturing facility in Europe producing peanut oral immunotherapy, said Sherden Timmins, Chief Technology Officer.